Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP031
- Development stage
- Discontinued
- Lead developer
- Noscira
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NP031 is a small molecule investigational drug developed as a phosphodiesterase 4B (PDE4B) isoform inhibitor. It was studied for potential treatment of central nervous system (CNS) disorders, particularly Alzheimer's disease and other neurodegenerative conditions, as well as inflammatory and autoimmune diseases. The drug modulates PDE4B to increase cAMP levels, aiming to improve cognitive function and reduce neuroinflammation, though clinical development appears to have been discontinued following negative trial outcomes.
02
Targets
Beyond the preview
Go deeper on NP031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP031.